Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFTISARC-NEO: Pembrolizumab + eftilagimod alpha with radiotherapy as neoadjuvant treatment for resectable soft tissue sarcomas
2022-003845-36Phase 2Active
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and eftilagimod alpha in soft tissue sarcoma (STS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: pathological response. Started Feb 2023; status: active.
02
Drugs
pembrolizumabeftilagimod alpha
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2022-003845-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003845-36.